Abstract
The last quarter of a century has witnessed remarkable progress in the understanding of phosphoinositide 3-kinases (PI3K) signalling and their involvement in different diseases such as cancer, diabetes and inflammation. Nevertheless, many questions remain open and among these the role of genetic and epigenetic regulation of PI3K isoforms is one of the most prominent. Emerging evidence Indicates that levels of isoforms can be modulated upon stimulation or in both physiological and pathological conditions including increased gene copy number and transcription regulation. In addition, an intriguing role for epigenetic regulation of PI3K expression, caused by mechanisms other than changes in the underlying DNA sequence, are starting to get appreciated. In this review, we summarize the genetic and epigenetic regulation of PI3Ks in physiology and the role played by their alterations in different diseases.
Keywords: PI3K, genetic, epigenetic, cancer, SNP, mutations, regulation
Current Pharmaceutical Design
Title:Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms
Volume: 19 Issue: 4
Author(s): Chanse Fyffe, Richard Buus, Marco Falasca
Affiliation:
Keywords: PI3K, genetic, epigenetic, cancer, SNP, mutations, regulation
Abstract: The last quarter of a century has witnessed remarkable progress in the understanding of phosphoinositide 3-kinases (PI3K) signalling and their involvement in different diseases such as cancer, diabetes and inflammation. Nevertheless, many questions remain open and among these the role of genetic and epigenetic regulation of PI3K isoforms is one of the most prominent. Emerging evidence Indicates that levels of isoforms can be modulated upon stimulation or in both physiological and pathological conditions including increased gene copy number and transcription regulation. In addition, an intriguing role for epigenetic regulation of PI3K expression, caused by mechanisms other than changes in the underlying DNA sequence, are starting to get appreciated. In this review, we summarize the genetic and epigenetic regulation of PI3Ks in physiology and the role played by their alterations in different diseases.
Export Options
About this article
Cite this article as:
Chanse Fyffe, Richard Buus, Marco Falasca , Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms, Current Pharmaceutical Design 2013; 19 (4) . https://dx.doi.org/10.2174/1381612811306040680
DOI https://dx.doi.org/10.2174/1381612811306040680 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Methods for the Non-Invasive Administration of DNA Therapeutics and Vaccines
Current Drug Delivery Biomedical Applications of Accelerator Mass Spectrometry
Current Analytical Chemistry Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Current Medicinal Chemistry New Directions for Clinical Trials of Targeted Alpha Therapy for Metastatic Melanoma
Current Radiopharmaceuticals Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?
Mini-Reviews in Medicinal Chemistry Vesicovaginal Fistula
Current Women`s Health Reviews Hybrid PET/MRI for In Vivo Imaging of Cancer: Current Clinical Experiences and Recent Advances
Current Medical Imaging Organocatalytic Synthesis and Antitumor Activity of Novel 1,2,3-triazoles Derived from Fatty β-ketoesters
Medicinal Chemistry Role of Lipoxins and Resolvins as Anti-Inflammatory and Proresolving Mediators in Colon Cancer
Current Molecular Medicine Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results
Current Drug Targets Garlic and its Active Compounds: A Potential Candidate in The Prevention of Cancer by Modulating Various Cell Signalling Pathways
Anti-Cancer Agents in Medicinal Chemistry Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
Current Vascular Pharmacology Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine